Hyperuricemia Aggravates IgA Nephropathy

Document Type : Letter to Editor

Authors

1 Professor, Medical Plants Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran

2 General Practitioner, Plants Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran

3 Professor, Department of Nephrology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

It is well documented that hyperuricemia is an independent risk factor for IgA nephropathy, and appropriate treatment by allopurinol is a reasonable modality in the patients. We believe that, this drug should routinely be included to the treatment of patients with IgA nephropathy. In this regard, to better understand the allopurinol kidney protective properties in IgA nephropathy, clinical studies are suggested.

References

  1. Barratt J, Feehally J. Primary IgA nephropathy: new insights into pathogenesis. Semin Nephrol 2011; 31(4): 349-60.
  2. Nasri H, Mortazavi M, Ghorbani A, Shahbazian H, Kheiri S, Baradaran A, et al. Oxford-MEST classification in IgA nephropathy patients: A report from Iran. J Nephropathol 2012; 1(1): 31-42.
  3. Baradaran A. Comment on: Association between the proportion of globally sclerotic glomeruli and various morphologic variables and clinical data of IgA nephropathy patients. J Ren Inj Prev 2012; 1(1): 9-10.
  4. Nasri H, Ardalan MR. Association between the proportion of globally sclerotic glomeruli and various morphologic variables and clinical data of IgA nephropathy patients. J Ren Inj Prev 2012; 1(1): 27-30.
  5. Herzenberg AM, Fogo AB, Reich HN, Troyanov S, Bavbek N, Massat AE, et al. Validation of the Oxford classification of IgA nephropathy. Kidney Int 2011; 80(3): 310-7.
  6. Nasri H, Sajjadieh S, Mardani S, Momeni A, Merikhi A, Madihi Y, et al. Correlation of immunostaining findings with demographic data and variables of Oxford classification in IgA nephropathy. J Nephropathol 2013; 2(3): 190-5.
  7. Rafieian-Kopaei M, Baradaran A. Combination of metformin with other antioxidants may increase its renoprotective efficacy. J Ren Inj Prev 2013; 2(2): 35-36.
  8. Mubarak M. Significance of immunohistochemical findings in Oxford classification of IgA nephropathy: The need for more validation studies. J Nephropathol 2013; 2(3): 210-3.
  9. Mubarak M. Oxford classification of IgA nephropathy: Broadening the scope of the classification. J Nephropathol 2012; 1(1): 13-6.
  10. Ohno I. Relationship between hyperuricemia and chronic kidney disease. Nucleosides Nucleotides Nucleic Acids 2011; 30(12): 1039-44.
  11. Gheissari A, Hemmatzadeh S, Merrikhi A, Fadaei Tehrani S, Madihi Y. Chronic kidney disease in children: A report from a tertiary care center over 11 years. J Nephropathol 2012; 1(3): 177-82.
  12. Nasri H, Mubarak M. Significance of vasculopathy in IgA nephropathy patients with regard to Oxford classification and immunostaining findings: a single center experience. J Ren Inj Prev 2013; 2(2): 41-5.
  13. Vafa M, Mohammadi F, Shidfar F, Sormaghi MS, Heidari I, Golestan B, et al. Effects of cinnamon consumption on glycemic status, lipid profile and body composition in type 2 diabetic patients. Int J Prev Med 2012; 3(8): 531-6.
  14. Sulikowska B, Johnson RJ, Odrowaz-Sypniewska G, Manitius J. Uric acid, renal vasoconstriction and erythropoietin relationship in IgA nephropathy revealed by dopamine-induced glomerular filtration response. Kidney Blood Press Res 2012; 35(3): 161-6.
  15. Gheissari A, Javanmard SH, Shirzadi R, Amini M, Khalili N. The effects of blocking Angiotensin receptors on early stages of diabetic nephropathy. Int J Prev Med 2012; 3(7): 477-82.
Journal of Isfahan Medical School
Volume 31, Issue 253 - Serial Number 253
July and August 2013
Pages 1518-1521

Files

History

  • Receive Date: 07 June 2013
  • Revise Date: 15 May 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics